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Abstract: Background: Oral immunotherapy (OIT) can lead to desensitization to food allergens, but
patients can experience treatment-related symptoms of allergic reactions that cause anxiety and treatment
dropout. Interventions to improve OIT for patients are needed. Objective: To determine whether
fostering the mindset that non–life-threatening symptoms during OIT can signal desensitization improves
treatment experience and outcomes. Methods: In a randomized, blinded, controlled phase II study, 50
children/adolescents (28% girls, aged 7-17 years, M = 10.82, standard deviation = 3.01) completed 6-
month OIT for peanut allergies. Patients and their parent(s) had monthly clinic visits at the Sean N.
Parker Center for Allergy and Asthma Research between January 5, 2017, and August 3, 2017. All
families received identical symptom management training. In a 1:1 approach, 24 patients and their
families were informed that non–life-threatening symptoms during OIT were unfortunate side effects of
treatment, and 26 patients and their families were informed that non–life-threatening symptoms could
signal desensitization. Families participated in activities to reinforce these symptom mindsets. Results:
Compared with families informed that symptoms are side effects, families informed that symptoms can
signal desensitization were less anxious (B = −0.46, 95% confidence interval [CI]: −0.76 to −0.16; P
= .003), less likely to contact staff about symptoms (5/24 [9.4%] vs 27/154 [17.5%] instances; P =
.036), experienced fewer non–life-threatening symptoms as doses increased (BInteraction = −0.54, 95%
CI: −0.83 to −0.27; P < .001), less likely to skip/reduce doses (1/26 [4%] vs 5/24 [21%] patients; P
= .065), and showed a greater increase in patient peanut-specific blood IgG4 levels (BInteraction =
0.76, 95% CI: 0.36 to 1.17; P < .001). Conclusions: Fostering the mindset that symptoms can signal
desensitization improves OIT experience and outcomes. Changing how providers inform patients about
non–life-threatening symptoms is a promising avenue for improving treatment.
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Abstract:  40 
Background: Oral immunotherapy (OIT) can lead to desensitization to food allergens, but 41 
patients can experience treatment-related symptoms of allergic reactions that cause anxiety and 42 
treatment dropout. Interventions to improve OIT for patients are needed.  43 
Objective: To determine whether fostering the mindset that non-life-threatening symptoms 44 
during OIT can signal desensitization improves treatment experience and outcomes.  45 
Methods: In a randomized, blinded, controlled phase II study, 50 children/adolescents (28% 46 
girls, aged 7-17, M=10.82, SD=3.01) completed six-month OIT for peanut allergies. Patients 47 
and their parent(s) had monthly clinic visits at the Sean N. Parker Center for Allergy & Asthma 48 
Research between 1/5/2017-8/3/2017. All families received identical symptom management 49 
training. In a 1:1 approach, 24 patients and their families were informed that non-life-50 
threatening symptoms during OIT were unfortunate side effects of treatment, and 26 patients 51 
and their families were informed that non-life-threatening symptoms could signal 52 
desensitization. Families participated in activities to reinforce these symptom mindsets. 53 
Results: Compared to families informed that symptoms are side effects, families informed that 54 
symptoms can signal desensitization were less anxious (B=-0.46, 95% CI (-0.76 to -0.16), 55 
p=0.003), less likely to contact staff about symptoms (5/24[9.4%] vs. 27/154[17.5%] instances, 56 
p=0.036), experienced fewer non-life-threatening symptoms as doses increased (BInteraction=-57 
0.54(-0.83 to -0.27), p<0.001), less likely to skip/reduce doses (1/26[4%] vs. 5/24[21%] 58 
patients, p=0.065), and showed greater increase in patient peanut-specific blood IgG4 levels 59 
(BInteraction=0.76(0.36 to 1.17), p<0.001). 60 
 4 
Conclusion: Fostering the mindset that symptoms can signal desensitization improves OIT 61 
experience and outcomes. Changing how providers inform patients about non-life-threatening 62 
symptoms is a promising avenue for improving treatment. 63 
Trial Registration: clinicaltrials.gov NCT03513965 64 
 65 






What is already known about this topic? Past studies have explored different ways of 71 
framing the prevalence of side effects to reduce their occurrence. No previously published 72 
studies have investigated the consequences of changing patients’ mindsets about symptoms. 73 
 74 
What does this article add to our knowledge? This is the first study to show that informing 75 
oral immunotherapy (OIT) patients that non-life-threatening symptoms of OIT can signal 76 
increasing desensitization can reduce patient and family anxiety and improve treatment 77 
experience and outcomes. 78 
 79 
How does this study impact current management guidelines? This study provides initial 80 
evidence for a novel, promising strategy to improve OIT treatment experience and outcomes. It 81 
suggests that changing how providers inform patients about non-life-threatening symptoms of 82 
OIT will benefit patients and their families. 83 
 84 
Keywords: allergy, food allergy, oral immunotherapy, peanut allergy, mindsets, patient 85 
experience, allergic symptoms, pediatric allergy 86 
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Abbreviations:  88 
IgE=immunoglobulin E antibodies. 89 
IgG4=immunoglobulin G antibodies. 90 
IRB=Institutional Review Board. 91 
 6 
OIT=oral immunotherapy.  92 
SAPS = “Symptoms as Positive Signals” condition, in which patients and their parent(s) 93 
were informed that non-life-threatening symptoms during OIT could be associated with 94 
desensitization.  95 
SASE = “Symptoms as Side Effects” condition, in which patients and their parent(s) were 96 
informed that non-life-threatening symptoms during OIT are unfortunate side effects of 97 
treatment.  98 






Approximately 5.9 million American children/adolescents have a food allergy.1 Oral 104 
immunotherapy (OIT) is a promising treatment2 in which patients consume gradually 105 
increasing doses of their allergen to build desensitization, which protects from accidental 106 
exposure and improves quality of life.3 Some patients experience allergic symptoms after 107 
consuming doses.4,5 Non-life-threatening symptoms patients may experience (e.g., itchy 108 
mouth, congestion) are generally mild, but may nonetheless provoke anxiety because of their 109 
association with allergic reactions. Symptoms can even prevent treatment completion.5-7 110 
Evidence-based strategies for improving OIT experience are needed. 111 
Providers have an ethical responsibility to inform patients about possible treatment-related 112 
symptoms. However, the relationship of symptoms to treatment is often multifaceted and 113 
symptoms are sometimes associated with healing. For example, fevers, while uncomfortable, 114 
signal that the body is fighting infection and aid healing (e.g., bolstering immune function).8 115 
Wound inflammation (e.g., swelling) indicates that mast cells are releasing enzymes, 116 
histamines, and other amines as part of healing.9 Delayed onset muscle soreness (DOMS) 117 
occurs when muscles are used vigorously, perhaps because of muscle micro-damage and 118 
inflammation,10 but can signal that the body is strengthening. Symptoms during OIT could be 119 
interpreted similarly. Desensitization is believed to begin with the uptake of allergens in the 120 
mucosa of the oral cavity,2 which might be associated with mild, transient symptoms like itchy 121 
mouth and/or congestion. Non-life-threatening symptoms could thus be understood as evidence 122 
that the treatment is active in the body and possibly increasing desensitization. Although the 123 
effects of symptoms are complex, patients may focus solely on negative aspects (e.g., 124 
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discomfort) and fail to recognize that symptoms can be associated with treatment progress. For 125 
example, people are often unaware that fevers are part of healing and over-treat them.11 126 
A person’s mindset, or the particular lens through which information is perceived and 127 
interpreted, simplifies many possible interpretations of complex realities such as the 128 
relationship between symptoms and treatment. For example, past research has shown that 129 
people adopt different mindsets about stress: that it tends to have detrimental health effects 130 
(e.g., increasing disease risk) or that it can have beneficial health effects (e.g., enhancing 131 
cognitive function).12 The true nature of stress is paradoxical; it can be both enhancing and 132 
debilitating. But informing people that stress can be enhancing shifts their mindsets about 133 
stress (i.e., what they focus on and therefore expect) to selectively interpret stress as enhancing, 134 
which consequently shapes responses to stressors.12-14 By orienting a person toward one aspect 135 
of a complex reality, mindsets influence how people interpret and experience health-relevant 136 
situations and their health outcomes.12-20  137 
When providers inform patients about possible symptoms, distinguish between life-threatening 138 
and non-life-threatening symptoms, and teach patients strategies for managing symptoms, they 139 
may unintentionally convey the message that symptoms are a negative aspect of treatment that 140 
should be avoided. This “symptoms as side effects” mindset may lead to anxiety and 141 
discouragement, a tendency to interpret symptoms as a sign that treatment is going poorly, and 142 
skipping doses to avoid symptoms. Alternatively, if providers additionally inform patients that 143 
non-life-threatening symptoms can sometimes signal that treatment is progressing positively 144 
into desensitization, it may prompt patients who experience these symptoms to adopt a mindset 145 
of symptoms as positive signals that the treatment is active in the body, and that it is potentially 146 
improving outcomes (i.e., desensitization). Although patients with a “symptoms as positive 147 
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signals” mindset may still be uncomfortable while experiencing mild symptoms, these 148 
symptoms may be interpreted as a positive signal that treatment is progressing as expected, 149 
towards desensitization. These patients may then feel less anxious about symptoms and be less 150 
likely to skip doses to avoid symptoms or drop out of OIT. The most effective and safe 151 
treatment would teach patients to treat non-life-threatening and life-threatening symptoms in an 152 
evidence-based, standardized fashion while at the same time helping them to adopt useful 153 
mindsets about non-life-threatening symptoms. 154 
The current study sought to experimentally examine whether changing mindsets about non-155 
life-threatening symptoms during OIT improves treatment experience and outcomes. 156 
Compared to the more typical approach of informing patients and parents that “symptoms are 157 
unfortunate side effects of treatment,” fostering the mindset of “symptoms as positive signals” 158 
that can be associated with desensitization may improve subsequent OIT outcomes. 159 
Methods 160 
Study Design 161 
This was a parallel, randomized phase II controlled trial conducted from 1/5/2017 to 8/3/2017. 162 
All procedures were approved by Stanford University’s Institutional Review Board (IRB, 163 
Protocol #36282). Adults provided written informed consent and children/adolescents provided 164 
written assent. Study registered on clinicaltrials.gov (NCT03513965).  165 
Participants 166 
The Sean N. Parker Center for Allergy & Asthma Research at Stanford University (SNPC) 167 
recruited fifty patients aged 7-17 (power analysis in Methods, Online Repository). Eligible 168 
patients either had peanut-specific blood IgE (immunoglobulin E antibodies) level ≥60 Ku/L, 169 
or peanut-specific IgE levels <60 with peanut-specific skin prick test greater than 3mm and 170 
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peanut-specific IgE >5 Ku/L. Patients with anxiety and/or mood disorders (e.g., generalized 171 
anxiety disorder, bipolar disorder) diagnosed by a mental healthcare professional were 172 
excluded, following standard SNPC protocols. One potential participant was excluded on this 173 
basis. Additional detail and exclusion criteria in Methods, Online Repository.  174 
Procedures and Intervention 175 
Patients consumed doses at home over 24 weeks (dosing schedule in Table E1, Online 176 
Repository). Families were randomly assigned to either the “Symptoms as Positive Signals” 177 
(SAPS) condition or the “Symptoms as Side Effects” (SASE) condition. SAPS and SASE 178 
groups never interacted.  179 
Families attended monthly group clinic visits by condition (six to seven patients per group) at 180 
SNPC throughout the 7-month study to participate in treatment-relevant activities. Each parent 181 
had a monthly call with the head of the patient support team, during which parents could 182 
express concerns about treatment or symptoms. Parents were encouraged to contact the head of 183 
the patient support team and/or the physician administering treatment with questions/concerns 184 
anytime. 185 
Both groups received identical OIT instructions, including practical dosing strategies and 186 
symptom management (Appendix EA, Online Repository). To promote safety, all families 187 
were given identical training medication use (e.g., antihistamines) for non-life-threatening 188 
symptoms and comprehensive instructions for recognizing potentially life-threatening 189 
symptoms and administering injectable epinephrine when appropriate. Families were provided 190 
with materials to remind them of these steps (Figure E1, Online Repository). All families had 191 
the same access to resources (e.g., staff support) and patients’ symptoms were carefully 192 
monitored.  193 
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SAPS families were additionally encouraged to think of symptoms as a positive signal 194 
associated with increasing desensitization. This mindset was reinforced using written 195 
information (Figure E2, Online Repository) and activities (Table 2) at monthly clinic visits 196 
throughout OIT (details in Methods, Online Repository). For example, children wrote letters to 197 
their “future selves” including either a reminder of a way to manage symptoms or a reminder 198 
that symptoms can signal that treatment is working. Mindsets were reinforced through direct 199 
communication with the patient support team when appropriate.  200 
Randomization and Masking 201 
SNPC staff and study personnel enrolled patients in the study. In a 1:1 approach, at enrollment, 202 
eligible study patients were randomly assigned to either the SAPS or SASE groups by the 203 
specific time block of the study they attended (see Methods, Online Repository). 204 
Patients/parents were masked to group assignment. Because of the intervention’s nature, 205 
masking study personnel who delivered the intervention was not possible. 206 
Measures 207 
Patients and/or their parents completed daily online questionnaires through REDCap;21 208 
respondents indicated whether the child alone, parent alone, or parent/child together had 209 
completed the survey. Patients and parents each completed their own surveys at each monthly 210 
clinic visit. 211 
Endpoints - Treatment Experience 212 
Symptom mindsets: Patients/parents answered clinic survey questions about whether symptoms 213 
signal increasing desensitization (see measures in Methods, Online Repository).  214 
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Symptom anxiety: In clinic surveys, patients/parents who indicated that they/their child had 215 
experienced symptoms during the past month were asked how anxious they were about these 216 
symptoms (1=not worried at all, 4=extremely worried).  217 
Dosing experience: In REDCap, respondents indicated how well dosing went on a given day 218 
(1=very badly, 4=very well).  219 
Staff contact about symptoms: Researchers recorded how often parents contacted the patient 220 
support team with questions. An independent coder evaluated whether contact concerned 221 
symptoms.  222 
Symptom occurrence: In REDCap, respondents indicated if they had experienced symptoms 223 
after each dose (yes/no) and selected specific symptoms experienced. Non-life-threatening 224 
symptoms included: swelling of lips/face, itchy mouth/throat, itchy skin, stomach pain, nausea, 225 
nasal congestion, diarrhea, hives, rash/redness/blotchiness, light-headedness, other. Potentially 226 
serious symptoms included: trouble breathing, tightness in throat, repetitive cough, vomiting, 227 
voice change/hoarseness.  228 
Endpoints - Treatment Outcomes 229 
Adherence: In REDCap, respondents indicated whether they had taken a partial/no dose and 230 
why: 1=advised by patient support team, 2=due to illness not related to dosing, 3=forgot, 231 
4=due to travel, 5=no doses (e.g., ran out of supplies), 6=due to symptoms from dosing, 232 
7=apprehensive about a possible reaction, 8=other. Patients were coded as skipping/reducing a 233 
dose because of symptoms if they/their parents indicated they did not take their full dose 234 
because of symptoms or apprehension about reactions.  235 
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Time to treatment completion: Researchers recorded whether patients completed treatment 236 
within the scheduled 24 weeks, or whether it took them an additional two or more weeks (the 237 
time period between each scheduled updose) to reach the final updose. 238 
Biomarkers associated with desensitization: Blood samples were taken pre-OIT at the first 239 
clinic visit and again at 24 weeks for those patients who consented (14 SAPS patients, 16 240 
SASE patients) and assayed for peanut-specific blood IgE/IgG4 levels. Prior research suggests 241 
that IgG4 levels may indicate OIT-related desensitization,22-27 but offers mixed evidence as to 242 
whether IgE levels change during OIT, sometimes showing post-treatment decline.5,23 243 
Statistical Analysis 244 
Clinic survey and REDCap data were analyzed using multilevel longitudinal models; blood 245 
sample data were analyzed using multiple linear regression (additional details in Methods, 246 
Online Repository).  247 
Results - Participants 248 
Fifty children/adolescents (36 boys[72%], 14 girls[28%], 20 White[40%], 17 Asian[34%], one 249 
African-American[2%], 12 multiple race/ethnicity[24%]) with severe peanut allergies 250 
participated in the study. Patients were aged 7-17 (MAge=10.82, SD=3.01). Patients were 251 
recruited into the study from 11/14/2016 to 1/4/2017. For baseline characteristics, see Table 1. 252 
No patients withdrew from the study or were excluded from analyses (see Figure 1). Families 253 
reported high levels of anxiety about treatment (“How nervous are you about the dosing 254 
process?”, 1=not nervous at all, 4=extremely nervous) and symptoms (“How nervous are you 255 
about the possible symptoms or side effects of the dosing process?”, 1=not nervous at all, 256 
4=extremely nervous) (see Table 3). There were no baseline differences in groups in treatment-257 
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related anxiety (MSAPS=2.63, SD=0.99; MSASE=2.67, SD=1.02), t(90)=0.20, p=0.843, or 258 
symptom-related anxiety (MSAPS=2.84, SD=0.92; MSASE=2.72, SD=0.88), t(90)=-0.61, p=0.541. 259 
Results – Treatment Experience 260 
Effect on Symptom Mindsets 261 
SAPS families endorsed the mindset of symptoms as positive signals to a greater extent than 262 
SASE families, B=0.32, 95% CI (0.12 to 0.53), SE=0.10, t(67.05)=3.17, p=0.002. This 263 
difference persisted at three and six months post-treatment in an IRB-approved follow-up 264 
(Supplemental Analyses in Online Repository). Adoption of the mindset was also evident in 265 
participants’ open-ended responses from clinic visit activities (Appendix EB, Online 266 
Repository). Notably, families of SAPS patients who experienced no symptoms in a given 267 
month did not evince greater concern that the treatment might not be working than families of 268 
SASE patients who in a given month experienced no symptoms, B=-0.03(-0.24 to 0.18), 269 
SE=0.11, t(59.69)=-0.30, p=0.766; a lack of symptoms did not appear to become a negative 270 
signal in the SAPS condition. In both conditions, clinic sessions were evaluated equally 271 
positively (e.g., utility, enjoyableness), and families did not differ in perceptions of treatment 272 
efficac7 (Supplemental Analyses, Online Repository). Families thus had similar experiences 273 
except for the different symptom mindsets. 274 
Effect on Symptom Anxiety 275 
SAPS families whose child experienced symptoms during a given month reported being less 276 
anxious about these symptoms, B=-0.46(-0.76 to -0.16), SE=0.15, t(69.28)=-3.03, p=0.003 (see 277 
Figure 2). 278 
This pattern did not change over the course of treatment; an interaction with month was non-279 
significant, B=-0.05(-0.14 to 0.04], SE=0.05, t(54.55)=-1.10, p=0.277. This pattern did not 280 
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differ between patients and parents; when an interaction with respondent was included in the 281 
model, it was non-significant, B=-0.14(-0.74 to 0.47), SE=0.31, t(68.81)=-0.45, p=0.657.  282 
Effect on Dosing Experience 283 
SAPS families were less likely to report through REDCap that dosing had not gone well on 284 
days when symptoms occurred. Respondents reported that the dosing went “very well” for 285 
7,440/8,164[91.1%] doses, so we dichotomized the variable such that 0 indicated that a 286 
respondent reported that the dosing had gone very well, and 1 indicated otherwise. There was a 287 
significant interaction between intervention group and symptom occurrence, B=-1.81(-2.66 to -288 
0.99), SE=0.43, z=-4.25, p<0.001 (Figure E3, Online Repository). When no symptoms 289 
occurred, there was no difference between the two groups in how well respondents reported the 290 
dosing went, BSimpleEffect=0.38(-1.05 to 1.79), SE=0.71, z=0.54, p=0.592. But when patients did 291 
experience symptoms, respondents in the SAPS group were somewhat less likely to report that 292 
the dosing had not gone well, BSimpleEffect = -1.43(-2.92 to 0.00), SE=0.73, z=-1.96, p=0.050. In 293 
other words, SAPS families were less likely to associate symptoms with concerns that the 294 
treatment was going poorly. (Models including an interaction with assigned dose size did not 295 
converge, so it is unclear whether this varied over time.) 296 
Effect on Staff Contact About Symptoms 297 
SAPS parents were also less likely to contact staff with concerns about non-life-threatening 298 
symptoms (15/159[9.4%] instances) than SASE parents (27/154[17.5%] instances), χ2(1)=4.42, 299 
p=0.036, though the overall number of instances of contact (including calls regarding 300 
administrative issues, scheduling conflicts) did not differ by condition (Table E2, Online 301 
Repository).  302 
Effect on Symptom Occurrence 303 
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Most patients did not experience non-life-threatening symptoms from dosing (only 304 
538/8498[6.3%] doses resulted in symptoms), so we dichotomized the variable such that 1 305 
indicated a patient experienced at least one symptom, and 0 indicated a patient reported no 306 
symptoms (specific symptom rates in Table E3, Online Repository). 307 
When examining the occurrence of symptoms throughout the study period, there was a 308 
significant quadratic interaction such that SAPS patients were less likely to experience non-309 
life-threatening symptoms as dose sizes increased toward one peanut, B=-0.54(-0.83 to -0.27), 310 
SE=0.14, z=-3.88, p<0.001 (see Figure 4); the model including the quadratic interaction 311 
explained significantly more variance than a model with a linear interaction, χ2(2)=18.68, 312 
p<0.001. Floodlight testing28 revealed that, at the lowest dose size, conditions did not differ in 313 
the occurrence of non-life-threatening symptoms, B=0.09(-0.85 to 1.04), SE=0.46, z=0.19, 314 
p=0.849, nor did they halfway through treatment, B=0.45(-0.56 to 1.46), SE=0.50, z=0.91, 315 
p=0.365. However, at the largest dose size, SAPS patients were less likely to experience non-316 
life-threatening symptoms than SASE patients, B=-1.63(-2.85 to -0.42), SE=0.60, z=-2.69, 317 
p=0.007. Effects were similar for an analysis testing condition differences on all symptoms 318 
experienced (e.g., including potentially serious symptoms such as trouble breathing and 319 
vomiting, see Supplemental Analyses, Online Repository). No patient in the course of the 320 
study needed to use an injectable epinephrine device in response to symptoms.  321 
Results – Treatment Outcomes 322 
Effect on Adherence 323 
Few patients skipped/reduced doses because of symptom-related anxiety (6/50[12%] patients 324 
did at least once during treatment). One of 26 SAPS patients (4%) skipped or reduced a dose 325 
because of symptom-related anxiety, compared to five of 24 SASE patients (21%), χ2(1)=3.41, 326 
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p=0.065, offering preliminary evidence that the mindset intervention increased adherence.  327 
Effect on Time to Treatment Completion  328 
48 of 50 patients completed treatment in 24 weeks. Two SASE patients had a prolonged 329 
updose phase due to symptoms and completed treatment by 35 weeks. This rate of timely 330 
completion (100% for SAPS patients, and 92% for SASE patients) is greater than those 331 
observed in other studies (between 76% to 93% with various dosing schedules5-7).  332 
Effect on Biomarkers Associated with Desensitization 333 
Compared to baseline levels, SAPS patients’ IgG4 levels increased to a greater extent over 334 
treatment (MDiff=1.85, t(13)=6.91, p<0.001) than SASE patients (MDiff=1.31, t(15)=5.55, 335 
p<0.001), BInteraction=0.76(0.36 to 1.17), SE=0.20, t(26)=3.88, p<0.001 (see Figure 4). A 336 
nonparametric Mann-Whitney U-test assessing between-group differences in change in IgG4 337 
levels from pre-OIT to post-OIT (MedianSASE=1.47; MedianSAPS=4.16) showed similar results, 338 
W=75, p=0.065 (see Table E4 and Figure E6). SAPS and SASE patients did not differ in their 339 
changes in IgE levels, BInteraction=-0.03(-0.23 to 0.17), SE=0.10, t(26)=-0.35, p=0.732 (Figure 340 
E4, Online Repository), and also did not differ in their changes in IgG4/IgE ratios (Figure E5 341 
and Supplemental Analyses, Online Repository).  342 
Discussion  343 
Although all study patients had good outcomes (e.g., achieving desensitization by 35 weeks of 344 
treatment), the “symptoms as positive signals” mindset (SAPS condition) improved treatment 345 
experience (e.g., anxiety, symptom rates) and outcomes (e.g., adherence, change in peanut-346 
specific blood IgG4 levels) over-and-above the “symptoms are side effects” mindset (SASE 347 
condition). SAPS families reported less symptom-related anxiety and were less likely to 348 
contact staff with concerns about symptoms (notable because advising patients over phone/e-349 
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mail is demanding for providers, particularly when patients are anxious29). SAPS patients’ 350 
physical health also benefitted. SAPS patients were less likely to experience symptoms at the 351 
end of treatment when doses were highest and used real peanuts as opposed to peanut flour, 352 
which is notable because symptom occurrence can prevent or delay OIT completion.5-7 353 
Additionally, SAPS patients showed a greater increase in biomarkers associated with 354 
desensitization, indicating that changing mindsets bolstered a physiological marker related to 355 
OIT success. Importantly, these effects were achieved while distinguishing between life-356 
threatening and non-life-threatening symptoms, ensuring the safety of all patients. This aligns 357 
with a larger body of work suggesting that mindsets shape physiological health outcomes12-20 358 
and can influence the course of medical treatment.  359 
The difference in IgG4 increase between SAPS/SASE patients is important and intriguing. It is 360 
possible that SAPS patients experienced less overall stress, leading to fewer proinflammatory 361 
markers and more immunomodulatory markers and ultimately IgG4 synthesis. Or, SASE 362 
patients’ higher anxiety levels may have muted immunologic changes that otherwise would 363 
have occurred. The link between anxiety, stress, and the immune system is robust but further 364 
studies are needed to test the association between mindset changes and immune modulation.30 365 
The group format in which OIT was administered was not the central focus of the current 366 
study, but this format for delivering treatment differed from treatment-as-usual. Both SAPS 367 
and SASE conditions included ample social support for patients and parents, both from their 368 
fellow group members and from the patient support team, which may in part explain the high 369 
rates of treatment completion observed (>90% in each group vs. 76%-93% in existing studies5-370 
7). Indeed, patient and parent feedback in both groups indicated that this group format was 371 
extremely useful (Appendix EC, Online Repository). A qualitative review of these reports 372 
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suggests that the group format was equally beneficial for both groups with respect to learning 373 
about practical strategies and the treatment process as well as gaining emotional support and a 374 
sense of shared experience. At the same time, the group format may have also fostered further 375 
integration of the mindsets due to the social and normative influence embedded in group 376 
discussions.31,32 In light of these potential benefits of delivering OIT, future research should 377 
more directly evaluate how the social components intertwined in the group format might add to 378 
or interact with the mindset intervention to optimize patient outcomes as compared to treatment 379 
as it is typically delivered.15,16,33  380 
Limitations 381 
This initial research was conducted at a single site under the supervision of one healthcare 382 
provider; larger, multisite studies with diverse patient populations are needed. Findings 383 
regarding biomarkers are limited in that a subset of participants provided blood samples; larger 384 
studies are needed. This intervention involved several hour-long educational meetings; shorter 385 
interventions may be just as effective at changing mindsets.12,18 Future research should explore 386 
the effects of simpler interventions to alter mindset as well as directly evaluate the efficiency 387 
and added efficacy of the group format. Though steps were taken to prevent treatment diffusion 388 
(e.g., SAPS and SASE groups never interacted), over time, SASE families began to agree more 389 
that symptoms can be a positive signal, though at the conclusion of treatment SAPS families 390 
still endorsed this mindset marginally significantly more than SASE families (see 391 
Supplemental Analyses). This may be a result of repeatedly answering questions about this 392 
mindset during clinic surveys. The results of the current study may thus underestimate the 393 
effect of changing symptom mindsets. 394 
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Though patients and their parent(s) in the current study reported high levels of anxiety at 395 
baseline, patients with a diagnosed anxiety disorder were excluded. Future research should 396 
assess whether this intervention can benefit sensitive populations, such as those with clinical 397 
levels of anxiety. This initial research was conducted with peanut allergies (one of the most 398 
prevalent food allergies), and future research should test these strategies in the context of other 399 
allergies and conditions. These findings may apply to other treatments in which common 400 
symptoms can signal that a treatment is working (e.g., fevers resulting from vaccines are 401 
deemed normal, harmless, and possibly helpful34). 402 
Conclusions 403 
This research adds to a growing body of work suggesting the need to systematically understand 404 
and leverage the psychosocial factors influencing treatment outcomes.15,16,33 It demonstrates 405 
that treatment experience and outcomes (i.e., desensitization) can be improved by considering 406 
patient mindsets. Distinguishing between serious, debilitating side effects and mild symptoms 407 
that can signal treatment efficacy is a novel solution to the ethical and important need to 408 
disclose symptoms without causing unnecessary harm. These findings suggest that intervening 409 
to change patient mindsets about treatments broadly, and symptoms in particular, is a potential 410 
route for medical clinics and providers to help patients cope with challenging medical 411 
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Table 1. Baseline patient characteristics for all patients in the study, and patients who volunteered blood samples pre- and post-OIT, 









Patients (All) Patients (Blood 
Samples) 
Number of Patients 24 16 26 14 50  30 
Demographic 
characteristics 
      
Boys 17 (71%) 10 (63%) 19 (53%) 9 (64%) 36 (72%) 19 (63%) 
Girls 7 (29%) 6 (38%) 7 (50%) 5 (36%) 14 (28%) 11 (37%) 
Age  10.42 (2.75)  10.19 (2.99) 11.19 (3.24)  11.14 (3.16) 10.82 (3.01) 10.63 (3.06)  
White 10 (42%) 7 (44%) 10 (39%) 7 (50%) 20 (40%) 14 (47%) 
Asian 6 (25%) 5 (31% 11 (42%) 5 (36%) 17 (34%) 10 (33%) 
Latino 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
African American 1 (4%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 
Mixed Race 7 (29%) 4 (25%) 5 (19%) 2 (14%) 12 (24%) 6 (20%) 
       
Clinical 
characteristics 
      
Single Food Allergy 6 (25%) 5 (31%) 10 (39%) 6 (43%) 16 (32%) 11 (37%) 
Multiple Food 
Allergies 
18 (75%) 11 (69%) 16 (62%) 8 (57%) 34 (68%) 19 (63%) 
Peanut-specific blood 
IgE 
 94.54 (138.54) 
Median=59.6 
[0.66, 571.00] 
 61.26 (66.27) 
Median=45.25 
[3.90, 232.00] 





 2.08 (3.40) 
Median=0.67 
[0.06, 13.60] 
 1.83 (2.24) 
Median=0.72 
[0.01, 6.93] 




Note. Data are mean (SD) or n (%). For peanut-specific blood IgE and IgG4, ranges are presented in square brackets below medians. 
There were no statistically significant differences between SAPS and SASE groups (or SAPS and SASE patients who provided blood 
samples) in patient gender, age, race, or having a single or multiple food allergies. There were also no statistically significant 
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differences in patient peanut IgE baseline levels or peanut IgG4 baseline levels, either when comparing means in a t-test using log 
transformed data or when comparing medians in a Wilcoxon rank-sum test. OIT=oral immunotherapy. SASE = “Symptoms as Side 
Effects” condition, in which patients and their parent(s) were informed that non-life-threatening symptoms during OIT are unfortunate 
side effects of treatment. SAPS = “Symptoms as Positive Signals” condition, in which patients and their parent(s) were informed that 
non-life-threatening symptoms during OIT could be associated with desensitization. IgE=immunoglobulin E antibodies. 
IgG4=immunoglobulin G antibodies. 
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Table 2. Description of Clinic Visits 
Visit 1 • Consent 
• Treatment Instructions 
• Blood Draws 
• Introduction of Mindset about Symptoms 
• Group Introduction/Discussion 
Visit 2 • Group Check-in  
• Distribution of Magnets with Mindset 
Message (see Figure E7) 
• Updose Instructions 
• Review of Symptom Management Strategies 
• Letter Writing Activity 
Visit 3 • Group Check-in 
• Updose Instructions 
• Scenario Responses 
• Bingo Ice Breaker 
Visit 4 • Group Check-in 
• Updose Instructions 
• Immune System Illustration 
Visit 5 • Group Check-in 
• Updose Instructions 
• Letter Reading 
• Video Interviews 
Visit 6 • Updose Instructions 
• Life After Treatment 
• Reflection on Treatment 
Visit 7 • Maintenance Dose Instructions 
• Certificates of Study Completion 
• Blood Draws 
Visit 8 • Q&A with Nurse Practitioner  




Table 3. Baseline patient and parent anxiety, across study conditions and within the two treatment groups. 
 SASE 
Patients 
SAPS Patients  SASE Parents SAPS Parents Patients (All) Parents (All) 
Number of Patients 21 25 22 24 46  46 
Anxiety about 
Treatment 
      
Not nervous at all 5 (23.8%) 6 (24%) 2 (9.1%) 2 (8.3%) 11 (23.9%) 4 (8.7%) 
Not that nervous 3 (14.3%) 9 (36%) 7 (31.8%) 3 (12.5%) 12 (26.1%) 10 (21.7%) 
Kind of nervous  9 (42.9%)  7 (28%) 7 (31.8%)  12 (50%) 16 (34.8%) 19 (41.3%)  
Extremely nervous 4 (19%) 3 (12%) 6 (27.3%) 7 (29.2%) 7 (15.2%) 13 (28.3%) 
       
Anxiety about 
Symptoms 
      
Not nervous at all 4 (19%) 4 (16%) 0 (0%) 1 (4.2%) 8 (17.4%) 1 (37%) 
Not that nervous 7 (33.3%) 8 (32%) 5 (22.7%) 2 (8.3%) 15 (32.6%) 7 (63%) 
Kind of nervous 9 (42.9%) 9 (36%) 10 (45.5%) 13 (54.2%) 18 (39.1%) 23 (110.37) 
Extremely nervous  1 (4.8%) 4 (16%) 7 (31.8%) 8 (33.3%) 5 (10.9%) 15 (2.87) 
 
Note. Data are n (%). Baseline data are missing for four patients and two parents; patients and/or parents were able to skip any survey 
questions and thus do not have responses to these questions. SASE = “Symptoms as Side Effects” condition, in which patients and 
their parent(s) were informed that non-life-threatening symptoms during OIT are unfortunate side effects of treatment. SAPS = 
“Symptoms as Positive Signals” condition, in which patients and their parent(s) were informed that non-life-threatening symptoms 
during OIT could be associated with desensitization.  
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